Bulletin "Veterinary biotechnology"

Veterynarna biotehnologija – Veterinary biotechnology, 2016, 28, 208-216 [in Ukrainian].

NIKITOVA A.P., e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., POLUPAN I.M., e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.,NYCHYK S.A., e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ROZUMNYUK A.V., e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Institute of Veterinary Medicineof NAAS

NEDOSEKOV V.V., e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

National University of Life and Environmental Sciences of Ukraine

IVANOV M.JU., e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

State Research Institute of Laboratory Diagnostics and Veterinary and Sanitary Expertise


Introduction. Biorisk generally refers to the risk associated with biological materials and/or infectious agents. An international Laboratory Biorisk Management Standard developed under the auspices of the European Committee for Standardization, defines biorisk as the combination of the probability of occurrence of harm and the severity of that harm where the source of harm is a biological agent or toxin.

The goal of the work. Analysis of biorisks of rabies virus spreading in the laboratory and its prevention.

Materials and methods of research. In our research we used the standard of rabies vaccine – International Working Standard (IWS) of Rabies Vaccine I.P. and commercial rabies vaccine Rabistar. For direction rabies virus in pathological materials on bioassay method and serological testing of rabies vaccines we used white mice weighing 9–15 g. For the detection of antibodies to the rabies virus we used test device BIO RAD Platelia Rabies Kit II.

Results of research and discussion. The article presents main requirements of organization biosafety system in laboratory during work with rabies virus, describe main methods that are used in laboratory during diagnostics, testing of vaccines, making screening, monitoring and molecular-genetic researches. As a result of use model VDP (valuation, decrease and productivity) for decreasing of biosecurity factor influence, authors proposed to make changes in working process. These changes do not reduce the effectiveness of the work while we are testing serum of blood, definition of potency of inactivated rabies vaccines, obtaining brain material and identification of rabies virus.

In this work, that involves testing serum of blood, was eliminated factor of risk (rabies virus) by changing work in vivo for in vitro.

The article showed that serological analysis is fast method for testing potency of inactivated rabies vaccines. Thus, duration of examination declines to 14 days and used less amount of mice that makes it effective and not expensive. It is required for safe work of laboratories staff, because test doesn't use live rabies virus. Presented method can be alternative for classic method NIH for testing potency rabies vaccines.

Using of developed scheme, that based on three time defrost-melt of brain material, gives an opportunity to get brain suspension of rabies virus with maximum high titer of infection potency after elimination of contamination laboratory equipment and instruments for minimizing danger for life of staff.

Results of RT-PCR in 100 % replied to results of biotest. It enables to use of RT-PCR method as diagnostic and screening test for identification isolates to make the collection of it.

Conclusions and prospects for further research. Proposed methodic have scientific novelty (confirmed by patents of Ukraine 47938 and 99046), simple, express by making them and decrease biorisk level in laboratory during scientific researches with rabies virus.

Keywords: rabies, biorisk, biosafety, NIH method, mouse inoculation test (MIT), ELISA, RT-PCR.


  1. Mіnіsterstvo ohoroni zdorov’ja Ukraini (1999). Bezpeka roboti z mіkroorganіzmami I–II grup patogennostі [Safety precautions with microorganisms of I-II groups of pathogenicity]. Kyi’v [in Ukrainian].
  2. Sandia National Laboratories. International Biological and Chemical Threat Reduction Program: biosecurity.sandia.gov/gbrmc.
  3. Nedosekov, V.V., Gryshok, L.P. & Polupan, I.M. (2010). Sposіb otrimannja mozkovoї suspenzії vіrusu skazu [Method for preparing suspension of rabies virus from brain]. Patent na korysnu model, 47938, 4 [in Ukrainian].
  4. Nikitova, A.P., Nedosekov, V.V. & Polupan, I.M. (2015). Sposіb viznachennja іmunogennoї aktivnostі іnaktivovanih antirabіchnih vakcin z vikoristannjam kalіbruval'noї krivoї [Method determining of the potency of inactivated rabies vaccine using a calibration curve]). Patent na korysnu model, 99046, 9. [in Ukrainian].
  5. Іvanov, M.Ju. (2011). Epіzootologіchna ta molekuljarno-bіologіchna harakteristika vulichnih іzoljatіv vіrusu skazu v Ukraїnі [Epizootological and molecular-biological characterization of street rabies virus isolates in Ukraine.] Extended abstract of  candidate’s thesis. Kyi’v [in Ukrainian].
  6. WHO (1996). Laboratory techniques in rabies (4 ed.). Geneva.
  7. Barth, R., Diderrich, G. & Weinmann, E. (1988). NIH test, a problematic method for testing potency of inactivated rabies vaccine. Vaccine, 6, 4, 369–377.
  8. Cliquet, F., Müller, T. & Mutinelli, F. (2003). Standardisation and establishment of a rabies ELISA test in European laboratories for assessing the efficacy of oral fox vaccination campaigns. Vaccine, 21, 2986–2993.
  9. Fournier-Caruana, J., Poirier, B.& Haond G. (2003). Inactivated rabies vaccine control and release: use of an ELISA method. Biologicals, 31, 1, 9–16.
  10. Gamoh, K., Senda, M. & Itoh O. (1996). Use of ELISA for in vitro potency test of rabies vaccines for animal use. Biologicals, 24, 2, 95–101.
  11. Krämer, B., Schildger, H. & Behrensdorf-Nicol, H. A. (2009). The rapid fluorescent focus inhibition test is a suitable method for batch potency testing of inactivated rabies vaccines. Biologicals, 37, 2, 119–126.
  12. Nedosekov, V. (2013). Critical review of the NIH-method for testing potency of inactivated rabies vaccines. Veterynarna medytsyna UkrainyVeterinary medicine of Ukraine, 10, 26–28 [in Ukrainian].
  13. Nedosekov, V.V., Polupan, I.M. & Ivanov, M.Yu. (2010). Sposib vyznachennya imunogennoyi aktyvnosti antyrabichnyx vakcyn [Method for determination of immunogenic activity of antirabic vaccines]. Patent na korysnu model, 47782, 4. [in Ukrainian].
  14. Nedosekov, V.V., Vyshnyakov, Y.F. & Gruzdev, K. N. (2001) Metody testirovaniia inaktivirovannykh antirabicheskikh vaktsin. [Methods for evaluating the potency of inactivated rabies vaccines are reviewed]. Voprosy virusologii – Virology questions, 5, 9-12 [in Russian].
  15. Perrin, P., Morgeaux, S. & Sureau, P. (1990). In vitro rabies vaccine potency appraisal by ELISA: advantages of the immunocapture method with a neutralizing anti-glycoprotein monoclonal antibody. Biologicals, 18, 321–330.
  16. Servat, A. & Cliquet, F. (2006). Collaborative study to evaluate a new ELISA test to monitor the effectiveness of rabies vaccination in domestic carnivores. Virus Research, Vol. 120, 17–27.
  17. Wasniewski, M. & Cliquet, F. (2012) Evaluation of ELISA for detection of rabies antibodies in domestic carnivores. Journal of Virological Methods, Vol. 179, 166–175.

Download full text in PDF